Holen Sie sich die Stockscreener-App
3.28
3.14%
0.10
Handel nachbörslich:
3.34
0.06
+1.83%
Schlusskurs vom Vortag:
$3.18
Offen:
$3.23
24-Stunden-Volumen:
3.58M
Relative Volume:
0.99
Marktkapitalisierung:
$912.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-241.99M
KGV:
-3.4934
EPS:
-0.9389
Netto-Cashflow:
$-133.64M
1W Leistung:
+4.46%
1M Leistung:
-4.09%
6M Leistung:
-34.00%
1J Leistung:
-33.74%
1-Tages-Spanne:
$3.23
$3.465
1-Wochen-Bereich:
$3.05
$3.465
52-Wochen-Spanne:
$2.61
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.28 | 884.97M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Wedbush | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology Inc (SANA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sana Biotechnology, Inc. Revenue Breakdown – NASDAQ:SANA - TradingView
SANA|Sana Biotechnology Inc|Price:3.190|Chg%:-0.020 - TradingKey
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SANA|Sana Biotechnology Inc|Price:3.215|Chg%:+0.095 - TradingKey
Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation - Seeking Alpha
Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Sana Biotechnology (SANA) Experiences Modest Decline as Stock Nears Support ZoneGolden Cross - dars.gov.et
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM - Yahoo Finance
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in FocusTick Index - dars.gov.et
Sana Biotechnology - Nasdaq
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D - The Manila Times
Sana Biotechnology Announces Follow-On Publication in The - GlobeNewswire
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Ko - The National Law Review
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)Contact Levi & Korsinsky Before May 20, 2025 - The National Law Review
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value IndexesWhat's Changed - simplywall.st
Sana Biotech heads to EASD with diabetes cell therapy update - Longevity.Technology
Sana Biotechnology (SANA) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar - Moomoo
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Form 4 Sana Biotechnology Inc For: 7 July By Investing.com - Investing.com Nigeria
Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares - Stock Titan
Sana Biotechnology (SANA) Surges Over 12% as Bulls Test Key ResistanceCombination Correction - dars.gov.et
SANA Should I Buy - Intellectia AI
SANA BIOTECHNOLOGY INC (SANA) Stock Chart - ChartMill
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative? - Sahm
Sana Biotechnology (SANA) Proxy filing Summary - Quartr
Sana Biotechnology (SANA) Q1 2026 earnings summary - Quartr
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 - The Manila Times
Sana Biotechnology Announces Symposium Presentation at the - GlobeNewswire
Citizens reiterates Sana Biotechnology stock rating on IND filing By Investing.com - Investing.com Canada
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Join Class Action to Recover Losses from Sana Biotechnology, Inc - The National Law Review
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025 - The National Law Review
Enterprise value to EBIT forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to earnings forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to book forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA) - TradingView
SANA Forecast — Price Target — Prediction for 2027 - TradingView
Sana Biotechnology (SANA) Edges Higher, Holds Above SupportActive ETF Flow - dars.gov.et
SANA News | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SANA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Shares HigherEarnings Beat Streak - dars.gov.et
Sana Biotechnology Inc (SANA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):